RxDoctor Payments DataLook up a doctor →

Melissa Knuckles, MD

Dermatology · Corbin, KYNPI 1821074360

Payments from drug & device makers

$1,600,013in general payments, 2019–2025

Across 2,686 payments — averaging $595.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$286K
  • Sun Pharmaceutical Industries Inc.$167K
  • Regeneron Healthcare Solutions, Inc.$165K
  • UCB, Inc.$155K
  • Sanofi$129K
  • LEO Pharma Inc.$112K
  • plus $587K from 36 others

What the payments were for

  • Consulting fees$164,66111%
  • Speaking & faculty fees$1,110,58476%
  • Travel & lodging$144,00010%
  • Food & beverage$43,1803%
  • Education$7820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,600,013 in reported general payments places this provider in the 95th percentile of 128 dermatology providers in Kentucky.

See all dermatology providers in Kentucky

Medicare billing

Part B allowed, 2024
$271,607
Medicare patients
986
Services billed
3,095

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab808$3,218,201
Skyrizi PenRisankizumab-Rzaa39$817,986
OtezlaApremilast162$776,356
Humira(Cf) PenAdalimumab64$709,397
AdbryTralokinumab-Ldrm160$605,602
TremfyaGuselkumab40$549,276
Cosentyx Sensoready (2 Pens)Secukinumab46$348,965
Bimzelx AutoinjectorBimekizumab-Bkzx23$340,724
Dupixent SyringeDupilumab72$280,408
RinvoqUpadacitinib39$256,577
SotyktuDeucravacitinib29$191,396
Cimzia (2 Pack)Certolizumab Pegol15$158,970
Adbry AutoinjectorTralokinumab-Ldrm35$129,204
Taltz AutoinjectorIxekizumab14$99,669
Xeljanz XrTofacitinib Citrate14$82,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$90,726$776,356162 claims
LEO Pharma Inc.Adbry$111,637$605,602160 claims
Johnson & JohnsonTremfya$2,668$549,27640 claims
AbbVieRinvoq$285,676$256,57739 claims
E.r. Squibb & Sons, L.L.C.Sotyktu$60,291$191,39629 claims
UCB, Inc.Cimzia (2 Pack)$154,590$158,97015 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCSiliq$43,677$64,36813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 128 dermatology providers in Kentucky.

Other dermatology in Corbin

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →